Navigation Links
Monoclonal Antibody Induces Death in Liver Cancer Cells

Researchers at the University of Pittsburgh School of Medicine have found that a newly available monoclonal antibody has the potential to induce death in liver cancer cells.

In a study, the monoclonal antibodies' use demonstrated significantly reduces tumour cell proliferation and survival in human and mouse hepotocellular cancer (HCC) cell lines.

The researchers say that the new findings have significant implications not only for the treatment of live cancer, but also for various other types of cancer-skin cancer, brain tumours, gastrointestinal tumours, prostate tumours, ovarian cancer and leukaemia.

According to the background information in an article published in the journal published in Molecular Cancer Therapeutics, most cases of HCC are secondary to either a viral hepatitis infection or cirrhosis of the liver.

Despite recent advances, it remains a disease of grim prognosis due to the poorly understood mechanism of how the disease originates and spreads. Most patients live only a short time after diagnosis.

Dr. Satdarshan P. Singh Monga, Associate Professor in the division of cellular and molecular pathology at the university, directed his colleagues to obtain rat and human liver cancer cell lines so as to analysed the cell lines for the levels of expression of an receptor tyrosine kinase (RTK) protein, shown to be highly active in the liver of HCC patients in some previous studies, known as platelet-derived growth factor receptor-alpha (PDGFRa).

The researchers also analysed the cells for their level of activation of the PDGFRa gene.

It was found that at an early foetal stage of liver development in the mouse, the level of expression of PDGFRa was 37 times higher compared to later stages of development in the adult mouse liver. The researchers also found significantly higher levels of PDGFRa in rat and human liver cancer cell lines as compared to normal ce lls in culture.

When both human and mouse live cancer cell lines were treated with a monoclonal antibody, tumour cell proliferation significantly decreased and programmed cell death (apoptosis) increased four to 18 fold, as compared to normal control cells.

The researchers say that the results depict PDGFRa as a possible new therapeutic target for the treatment of HCC.

"We are very excited because this is the first targeted therapy for liver cancer. Other therapies have some modest benefits, but no one knows exactly how they work. We now have identified a pathway that appears to be overly active in more than 70 per cent of the cancers we examined and, when targeted, leads to significant reduction in tumour cell proliferation and survival," said Dr. Monga.

He also says that targeting the PDGFRa pathway in liver cancer cells does not affect normal liver cells, making the treatment relatively non-toxic.

"Normally, regenerating liver cells are not exclusively dependent on this pathway, and it is not overly active in other types of cells. So this monoclonal antibody is a highly targeted treatment for this disease," he added.


'"/>




Related medicine news :

1. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
2. Monoclonal antibodies show promise in treatment of blood cancer
3. Monoclonal Anti-Body To Revolutionize Brain Cancer Treatment
4. Monoclonal Antibody based system for Anthrax detection
5. Monoclonal Antibody Reduces Exacerbations in Asthmatics
6. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
7. A New Monoclonal Antibody Kills Cancer Cells
8. Human Antibody That Can Block SARS
9. Cuba Registers New Antibody
10. Single Sugar Enables Antibody to Treat Inflammation
11. Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology: